| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2022 | 106.61% | Keybanc | $7 → $5 | Maintains | Overweight |
| 08/05/2022 | 189.26% | Keybanc | $10 → $7 | Maintains | Overweight |
| 11/10/2020 | 147.93% | Keybanc | → $6 | Initiates Coverage On | → Overweight |
| 02/27/2020 | 65.29% | Benchmark | $3.5 → $4 | Maintains | Speculative Buy |
Harvard Bioscience Questions & Answers
The latest price target for Harvard Bioscience (NASDAQ: HBIO) was reported by Keybanc on November 9, 2022. The analyst firm set a price target for $5.00 expecting HBIO to rise to within 12 months (a possible 106.61% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Harvard Bioscience (NASDAQ: HBIO) was provided by Keybanc, and Harvard Bioscience maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $7.00 to $5.00. The current price Harvard Bioscience (HBIO) is trading at is $2.42, which is out of the analyst's predicted range.